In the ever-evolving field of diabetes management, glucagon-like peptide-1 receptor agonists have emerged as a transformative therapeutic class. Among these, retaglutide, retatrutide, and trizepatide represent novel https://agnesexeg515621.blogprodesign.com/60321877/novel-glp-1-receptor-agonists-retaglutide-retatrutide-and-trizepatide